A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

NCT05503355 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

AML, Adult

Interventions

DRUG: BST-236
DRUG: venetoclax

Sponsor

BioSight Ltd.